24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy

NCT02243176 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

689

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Saxagliptin
DRUG: Acarbose

Sponsor

AstraZeneca